Podcasts about daiichi

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower. Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell carcinoma. Plus, the team compares notes from the ASCO exhibit hall. To learn more about the topics in this episode: ASCO: AstraZeneca, Daiichi flex Enhertu's muscles in first-line breast cancer as they drop new phase 3 gastric cancer data 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race ASCO: J&J highlights Rybrevant-Lazcluze combo in 'Breathtaking Moments' lung cancer campaign high over Chicago skyline See omnystudio.com/listener for privacy information.

2024 was a special year for Carnival and the Japan-New Orleans connection! Lafcadio Hearn's life & works inspired the theme for Rex Parade 2024: "The Two Worlds of Lafcadio Hearn - New Orleans & Japan". But why Hearn? What went into the float design? What other ways has Hearn left a lasting impact on both New Orleans & Japan? Find out today with a super-sized special Mardi Gras bonus episode, featuring insights from Rex historian/archivist Will French & historian/archivist emeritus Dr. Stephen Hales, Royal Artists float designer/artistic director Caroline Thomas, Lafcadio Hearn's great grandson Bon Koizumi,  legendary chef John Folse, Captain of the Krewe of Lafcadio John Kelly, JSNO's resident Lafcadio Hearn expert Matthew Smith, and even the Mayor of Matsue Akihito Uesada! Get ready for Mardi Gras 2025 by reflecting on this unique connection between New Orleans & Japan!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Music Credits ------Background music provided by: Royalty Free Music by Giorgio Di Campo for Free Sound Music http://freesoundmusic.eu FreeSoundMusic on Youtube  Link to Original Sound Clip------ Audio Clip Credits ------Thanks to Dominic Massa & everyone at WYES for allowing us to use some of the audio from the below Rex Clips:Segment about Royal Artist & Float DesignFull 2024 Rex Ball Coverage (Krewe of Lafcadio/Nicholls State segment)Thanks to Matsue City Hall & Mayor Akihito Uesada for their video message below:Message from Matsue Mayor Akihito Uesada------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan! ------ Past KOJ Hearn/Matsue/History Episodes ------Foreign-Born Samurai: William Adams ft. Nathan Ledbetter (Guest Host, Dr. Samantha Perez) (S5E17)Foreign-Born Samurai: Yasuke ft. Nathan Ledbetter (Guest Host, Dr. Samantha Perez) (S5E16)Explore Matsue ft. Nicholas McCullough (S4E19)Jokichi Takamine: The Earliest Bridge Between New Orleans & Japan ft. Stephen Lyman (S4E13)The Life & Legacy of Lafcadio Hearn ft. Bon & Shoko Koizumi (S1E9)Matsue & New Orleans: Sister Cities ft. Dr. Samantha Perez (S1E2)------ Links about Rex ------2024 Rex Parade/Float PDF with Full DesignsCaroline Thomas's Website------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

This season was a long one! The Krewe re-groups to reflect on Season 5 as a whole, and everything that went into it...  with a SPECIAL GUEST! Join us for one last audio journey in Season 5 as we discuss all the milestones, top moments, challenges, & fun anecdotes, in addition to a look ahead to Season 6 & listener feedback! Let's GO!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan! ------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

Host Dr. Davide Soldato and guests Dr. Suzanne George and Liz Salmi discuss their JCO article "Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality" TRANSCRIPT TO COME Dr. Davide Soldato: Hello and welcome to JCO's After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Liz Salmi, Researcher and Patient Advocate, and by Dr. Suzanne George, who works as a Medical Oncologist at the Dana-Farber Cancer Institute where she acts as the Chief of the Division of Sarcoma. She is also Associate Professor of Medicine at Harvard Medical School. Today, we are going to discuss with Suzanne and with Liz the article titled, “Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality.” So thank you for speaking with us, Suzanne, Liz. Liz Salmi: Thanks for having us. Dr. Suzanne George: Yes, thanks. Dr. Davide Soldato: I just want to make a brief introduction because I think that the concept of patient partner research is very wide and I'm not sure that all of the readers of JCO really have a deep understanding because I imagine that there are a lot of ways we can involve patient and patient advocates in the research process. And so I was wondering if you could give us a little bit of an introduction about the concept. Dr. Suzanne George: Sure. I think the point that you raise is really important because there are many terms that are used, patient-partnered research, patient advocacy, but I don't think that there's a single definition as to what that actually means. In the context of our work, we've sort of summarized our experience through something called the PE-CGS or the Participant Engagement and Cancer Genome Sequencing network. And in that project, which is a Moonshot funded network, the intention is to have participants in research be true partners working with traditional academic research teams in order to develop networks specifically focused on cancer genomics. So what we've done, every center is a little bit different in the network, but we're really having research participants not just act, but really work on the research team from the beginning of the project inception all the way through the research project. Liz Salmi: What brings me to the PE-CGS network is my 17 years experience as a person living with a low grade glioma, brain tumor or brain cancer and involving patients in the co-design of research is super critical because patients bring unique lived experiences that can shape research questions, study designs and outcome measures in ways researchers might not anticipate. And we're finding this through our network. So through my work, including my patient experience and brain tumor focused study designs, I've seen firsthand that patient insights can drive more practical implementations that ultimately benefit both patients and the researchers. And so the particular project I work on in the network, we've got like five different arms and different groups of cancer types that are being represented, so I'm basically focusing on the OPTIMUM study around how brain tumor patients can help in this study design. So in this project I serve as not just a participant in the research, but also as a patient co-investigator. Dr. Davide Soldato: That is very interesting. And I think that we really captured the essence of patient-partnered research by having both of you here talking with us about the PE-CGS. And the second question that I wanted to ask is: I really think that the network focuses on something that is quite important right now and currently in medical oncology - so cancer genome sequencing, access to novel therapies - and I think that it's really challenging to imagine a way in which we can really get our patient and get patient advocates to help us designing new trials who are looking into this. And I just wanted to know, do you think that there is something that is particularly challenging when we are speaking specifically about cancer genomics and access to this type of drugs that are targeting specific molecular alteration? Because I think that in general it might be a little bit easier, maybe I'm biased on this, so you can also tell me if I'm wrong, but I think that it's a little bit easier when we are trying to design, for example, behavioral intervention or things that are more commonly found in oncology and a little bit more complicated when we are speaking about genomics. Dr. Suzanne George: So I think that's part of what this network is trying to address, which is really what are the barriers and the opportunities around cancer genomics from the patient perspective and how do we make sure that that perspective is included as we're thinking about study design and inclusion? As Liz mentioned, this network has five different networks within the network, five different centers, and each center is slightly different with the population that it engages with. And so there's diversity there in terms of reaching out to different patient communities and partner communities around potential barriers for genomics research. I think one of the things though that we're finding across the network is that people want to be part of this work. People that have a lived experience of cancer want to help move the field forward. And what we ended up writing about was some of the barriers that get in the way of that. It's awesome to have people like Liz that are like all in and then there's people who are on the other end of the spectrum that want to share their information to help move the field forward around genomics, but then there's all these barriers at the systems level that get in the way of that. So I think that that's one of the challenges we're trying to overcome and learn about across the network. Liz Salmi: Yeah, I think I bring this really interesting, I can't say I'm really interesting, but I think I bring this really niche perspective. Not only am I a person living with a brain tumor and I'm a co-investigator but also like a participant in this study. I also, in my day job, I'm an investigator as part of the director of communications and patient initiatives on the OpenNotes lab at Beth Israel Deaconess Medical Center. And our lab really focuses on how open, transparent communication between doctors and patients improves care. And that's been going on for longer than I've been around on our team. But what I bring to that lab is I focus on engaging both patients and clinicians in spreading the awareness about the power of how easy access and transparent communication, access to information across healthcare settings helps patients feel more involved and informed in their care.   And I work specifically, it's a really niche area. I work on projects that aim to expand access to notes and test results in diverse care settings, really helping tailoring initiatives so that various patient communities can understand how they can be involved in these types of research projects. Ultimately that's what brought me into this space. I might be one of the first generation of patients that actually starts helping co-design studies on things like this. And I think that across a lot of healthcare settings cancer is really what we're focused on. But patients are now increasingly being involved as research collaborators. And there's many different funding institutions such as the NCI but also PCORI they now mandate that funders reflect a shift towards more patient centered research frameworks. So it's like the PE-CGS network isn't the only group that's being funded to do research in this way. And I think other investigators, even outside of the cancer space, but specifically in cancer, need to learn how to do research in this way. Dr. Suzanne George: Yeah, I agree. And I think the other thing that we need to do is if people want to participate and that participation in many of these networks has to do with record sharing and data sharing, the system needs to accommodate that. If people want to share their information in order to allow research to be performed, then we need to make sure that that can happen, and that it's not that the institution systems don't connect with someone else's systems or that you to pay X, Y and Z dollars for the data to go A, B and C, or that some places are on this EHR and some places are on that EHR and so, sure, you can share it, but you have to go through all of these hurdles in order to make it happen. When a patient signs a consent form that says, “I want my data to be used,” we as an investigator community, we owe it to that patient to make sure that their information is being part of the data set that will be used for learnings. And that's part of what we wrote about, is the lots of behind the scenes things that just get in the way and that we need to work towards improving. Liz Salmi: Both Suzanne and I are really passionate about this stuff. And as a person living with a brain tumor for the last 17 years, I'm a chronic research participant. I always, always, am really curious. I'm like, “Yes, let me contribute my data. Whether that's electronic health record data or maybe I'm being interviewed about certain aspects of the cancer care experience.” And the one thing that bummed me out for like the first 10 years of being this chronic research participant is I would enroll in things, I'd be interviewed for things, I'd fill out these surveys and then I never heard anything about what happened with that information and that time I spent. And people would send me like a $10 gift card to Amazon, like, “Thanks for participating,” but really what I wanted to know is like, did you do anything with that? How did that inform things? So that really annoyed me to the point where I was like, I'm just going to be part of the research process and really figure out how we share that information back to everybody who had spent so much time. And so my participation in this space is like, “Let's change it. Let's give people information back.” And now I know it takes a really long time to have a finding that could be published somewhere that we then get it back. But closing the loop on the communications gap is something I'm really passionate about. Dr. Davide Soldato: Do you think that we are changing a little bit this perspective? I feel like we are getting a little bit better in creating patient communities of patients who are included in specific clinical trials. And then we do the effort of creating a community, of keeping people really involved with the research that they are participating in. I think that we are not quite there yet, but I think that we are making some kind of steps in that direction. For example, trying also to inform patients to participate in the study when the publication that is related to that specific study comes out. What is the benefit? What have we discovered? I think that we are not quite there yet. There is a lot of room for improvement, particularly in the way I think we communicate these to patients who participated in research. But I have the impression that we are making some steps forward. So I don't know. Do you share the same thoughts? Liz Salmi: So Dr. George talked about the PE-CGS network and then there's five different cancer types being studied. So the thing I can reflect on is what we've done in the, this is a really long acronym but, Optimizing Molecular Characterization of Low Grade Glioma. Say that 10 times fast. So our particular group is people who donate tissues about their brain tumors. We're really collecting data from people with multiple brain surgeries over time, which is really complicated and to make that process easier. And then once those tissue samples are stored somewhere, studying that information about what changes in the brain tumors over time and then also giving those results back to people so they can take that research level data and bring it back to their neuro oncology team and say, “Hey. Here's what I found out, “and having a conversation. So, this is a long multi touch point study and in order to do that, to even make that possible is the individual patients need to understand what's in it for them. They're donating precious tissue in order to make the research process work. And so in order to do that, it's not just the investigators saying, “Hey. Give us your brain tissue, peace out.” It is we have a whole research advisory council of people living with these particular tumor types who help us co-design how do we do that outreach, how do we explain why this is important, or how do we message the importance of this work so they understand,“Oh, this is what's in it for me and this is what's in it for other people like me.” And from there then with that process, which again I mentioned, all of these multi-step processes, once we're able to understand how patients want to hear that information, what's in it for them, then we bring it back to like those bench scientists, investigators going, “Okay. And here's how this workflow should work for the patients,” and design everything around the patient experience before we even care about what's happening from the scientist researcher perspective. Dr. Suzanne George: I agree. I think to your point, I think the fact that we're all here today talking about this is just like you said, is that we are making progress, right? Like we're even here having this conversation. Just like you said, I think there's opportunities to improve and further refine the communication and the involvement back in the patient community. When I think- if I put on my clinical investigator hat, I'm very involved in PE-CGS, but my primary research interest historically has been clinical trials and drug development. And I think that our approach in communicating results back has just not been consistent. But I do think that there's opportunities, just like you said, to provide summaries of information to loop back. I don't think that we've completely solved: What do we do? How do we provide information back to loved ones of patients that may no longer be alive that participated? How do we provide information to people who maybe we don't have their contact information? What if we lose track of them? How do we also make sure that we give people the choice to know? Do you want to know about this or would you rather just participate and then give space to that research? Because maybe that's how people's best for them. So I think that you're right, we're making progress, but I think that there's also a lot more that we can do. So I'm glad we're talking about it. Dr. Davide Soldato: How much do you think that directly involving patients in this process, like asking them directly and co-designing the trial from the very beginning and understanding the level of information? This might also be another question inside of the question. So first, how much co-designing this type of research helps, and then do we also need to further refine at that level of communication, different communication depending on the level of information that different people want to have? Because I think that that's another level of complexity that we need to work towards at a certain point. We need to work on that first level of giving back the information. But then I think that there is also the other point of providing the information and information that should also be probably adapted to the cultural belief of different patients, to the ethnicity or to whatever cultural background or social background or whatever they may place their most interest in. Dr. Suzanne George: So I think that you're 100% right on all of those points. I think those are all topics that need to be considered. We may be able to get to a certain degree of granularity around those communication points, but on the other hand, we also want to be able to communicate broadly and accessibly as possible. One of the interesting things about PE-CGS, as Liz was mentioning, is each of the five centers has a slightly different focus. For example, one of the centers is focused on American Indians and Tribal Nations, and the communication practices coming out of that center are really unique and really very special and something that's been really, I think for me, very fascinating to hear about. Because to your point, like, just the strategy and what's considered appropriate is just different. I think if we hope to build a research world where our research participants and research data come from a broad swath of the population that really represents the population, the only way that we're going to be able to do that is find ways that bring meaning across the population as well. And that may be different based on where people are coming from and where people are at in their own journeys and in their own lives. But it's on us to be open to that and like to hear that, so we can do the right thing. Dr. Davide Soldato: And I think that this is one of the objectives of the PE-CGS, really trying to bring this type of research participation to really diverse and underrepresented populations, not only in terms of cultural background, but I also think about different types of tumors. Like Liz was referring about brain cancer or low grade glioma, which is a very niche population. And I also think about sarcomas, for example, the degree of variability that we have in that specific type of disease is such that we really need to probably find different ways to communicate also inside of this diversity in terms of single patient and experiences, but also in terms of single diseases. You were speaking a little bit before about the fact that the manuscript is really on the barriers that we would need to identify and then to change to make this system a reality. We were talking a little bit about consenting information and consenting the sharing of information, and I think that you make a very interesting point about the consent process when we are designing research. Could you give a little bit of your impressions about giving informed consent? What we need to change, how can we improve? Dr. Suzanne George: The bottom line is the consent process needs to be simple, clear, and transparent. And sometimes I feel, because the traditional way that we've always gone about consent is frequently consent is as it should be in many ways. These consent forms are developed from a regulatory framework. What are we required to do to consent and how do we meet those requirements? Sometimes that becomes directly at odds with how do we do this simply, clearly and transparently? And I think as a research community, we have to be able to find a common ground there. That has to include regulatory requirements, that has to include IRBs. When we think about consents and work with our patient communities on this, everybody agrees the consents need to be more simple, except the IRB or maybe the IRB agrees, but it's this tension between how do we make it simple, clear and transparent and not get so bogged down in the regulatory that we lose that intent. Liz Salmi: It's complicated. As a person, I mentioned, I'm a chronic research participant living with a brain tumor for 17 years. I remember enrolling in studies and seeing things that are just so complicated. I'm like, “Well, I'm just going to sign off.” I imagine somewhere somebody who knew more than me said, “I should just fill out this thing.” And then as I switched to the research world, I spent more time digging into, “Wow, this is a really complicated consent,” versus, “This is a really streamlined consent and I love this.” And throughout my work with Dr. George and others on the PE-CGS network, an example of a good consent that's easy for people to understand is what the NIH All Of Us research project did, where they're trying to get a million people, more than that, signed up to be in this longitudinal study. And their consent is to go to their website and they have a whole bunch of short YouTube videos. There's a kind of like a quiz involved and they're animated, they have multiple languages involved. And I signed up for that study and I was like, “This is a beautiful consent.” And it's a very plain language. And more consents like that. If you're looking for a good example, go there. I have not been paid by them in any way. I'm a participant in their study. I'm not sure if you guys and your listeners are aware, but there was I think, October 19th of this year or 2024, there was a special communication published in JAMA on an update on the Helsinki Principles for Medical Research involving human participants. And what they're saying is an ethical update is patient engagement in research, which emphasizes the need for continuous, meaningful engagement with research participants and their communities throughout the research life cycle, before, during and after studies. And so this is what we're talking about here. And it's now been embedded in these updated principles. Dr. Suzanne George: That's really great and I agree with you. I think the All Of Us consent process is very accessible. It feels like you can understand it. But the other thing is that, again, I also am not directly involved with All Of Us, but the other thing about it is that they also have a high-touch way to consent where they have navigators and people that will go into communities in a very resource intensive way. So there's all different ways to go about it. We need to find a way that we can balance the complexity around regulatory and the simplicity and transparency that we need in cancer research. Dr. Davide Soldato: Do you think that in terms of patient engagement we are doing better in academic sponsored research compared to sponsored research? A little bit of a provocative question maybe. Dr. Suzanne George: I think that's a really interesting question. I think this idea of participant engagement and involvement is being infused across the research community. And in part, the FDA has prioritized it as well. I think the industry sees the FDA prioritizing this as well. And I think that there are many companies that are involving participant and advocacy communities in different ways in the study design, in the study process early on. So I think it's happening. Liz Salmi: I'll be spicy. I've been a participant, I've been an investigator, co-investigator on studies and I have been reached out to often by pharma of, “Hey Liz, brain tumor patient advocate, would you be kind of like the poster child of our study or be involved in that way?” And I personally want to have no work in that space. I have no interest. However, I am approached, and other people living with cancer have been approached, by industry about lending their likeness or being commercials. And I don't think there's enough education to patient advocates of what that necessarily means, pros and cons. But I also can't speak on behalf of all of the patient advocates who might want to see that's a way that they could lend their voice and advance research. I personally think that there needs to be more involvement from the academic side of creating spaces where patients can be involved in the co-design of research and they also get compensated for their time fairly at the same level or some version of it in a way so they don't just jump to the pharma side of things. But that's an opinion that I have. Opinions. Dr. Suzanne George: I think it's really interesting the point that you make about providing more awareness or information about what it even means to do these things from a patient side. I certainly don't know that side as well, but I do see, often, the term patient advocate used very frequently in many different contexts that mean many different things. And I think that there's an opportunity there for understanding more about what that really means and what it can mean. Liz Salmi: Yeah. We want to involve patients, we want to do patient engagement. The BMJ or the British Medical Journal, have this new policy in place for patients as reviewers of research. And what I find interesting with the BMJ is they also ask patients to declare their conflicts of interest. So this is kind of a new space. If you're involved in patient research or perhaps working with pharma, patients, if you're involved at that level, should also be declaring their conflicts of interest if they're getting paid by a pharma. Or do I have a conflict now that I'm doing this cool ASCO podcast? Maybe. But do we want to overburden patients with tracking all this information? So it's a new world. The more we have access to information, the more we share information, the more we can read studies and we co-design, there's a new space I think over the next 5 to 10 years where how do we define this in a transparent way. Dr. Suzanne George: Yeah, I think you're right. I know that we're getting long, but I just want to say one other thing about that, which is that you're right. If we're bringing patients in to be partners, then we have to treat each other that way. We have to acknowledge- I think this issue that you raise about compensation and about paying people for their time or acknowledging people for their time, I think that's really important and very under-discussed. Liz and I were at the annual meeting for the PE-CGS and someone was there giving a talk about- this was a guest speaker that was giving a talk about a very large high impact grant and that included a patient advocacy kind of module, let's say. And they put in a specific funding and budget for that component that included compensation for the people- from the people in the advocacy community that were spending their time. And the PI of this project, again, not to get into the details of it, but they were sharing that they got a fair bit of pushback on that. But the PI pushed back and said, “Listen, we're compensating other people for their time. These guys, we want them to be partners, we need to treat them as such.” And I think that also again, kind of we're in a new space, but if we're going to do it right, then we have to acknowledge that we're partners. Dr. Davide Soldato: But I think that maybe an experience like the PE-CGS probably can be also a network for expanding awareness for patient advocates and also for creating sort of a new culture about what does that mean and how can we also improve on that part. Because in the end, if we want to engage, we also need to provide patients with the instruments to engage in a way that we think it's both useful for them, that can make research better, but can also make them at the exact same level as everyone who is participating in that research, which I think it's the bottom line of all the concepts that we are discussing right now. Liz Salmi: Yep. Dr. Suzanne George: Yes, I agree. Dr. Davide Soldato: So I think we have covered a lot of things. Just wanted to make one last reference to a point that Suzanne mentioned earlier, which is the interoperability of systems. And I think that when we come to the cancer genome, that is very important, being able to share information, especially for those diverse and less common cancer types that we were discussing earlier. There is a lot of work in gaining all that information and we need to be able to gather all of that information in the same place to advance research. You were mentioning before that the process is actually very complicated and I was wondering if in the network you are already working on some potential ways to address this type of issue. Dr. Suzanne George: I think our first step is really just calling it out, acknowledging how hard this is and what the barriers are. Oftentimes I think in research, we don't talk enough about what our methodologic barriers are. We talk more about what our results are, but not like how hard it is. But like in our projects, the Count Me In project, my network that I'm involved with, we're doing rare tumors. We can only do the United States and Canada because of privacy issues. And we're doing a completely web based platform. So we have the technology. But the privacy laws are impeding our ability to involve other parts of the world. And even within the United States, it's not as easy as we would like to get records. For example, despite the fact that people are saying, “Yes, use my records.” But then it's like, “Okay. Well, that's not that easy. How are we going to get them?” We had to hire a third party vendor in order to get the records, in order to manage all the different consents and releases that were needed across all these different hospital systems. So I think the first question is just calling it out and then from there working together as a community to try to see what the solutions can be, because we need to come up with those solutions. Liz Salmi: Yeah, we're in the same camp as Dr. George and the fact that of the five partners, we're not associated with one particular institution. So we can reach out around the country and get access to those records. And we need them at multiple points in time, over time and it takes a lot of effort and work. And it's not like you could just, say, call hospital A and they have all the information. It's like all of the calls to all of the other sites. And it's not just from one surgery, it's from two or more surgeries. But also the way that people stay involved, and, by people, I mean patients and family members, there's this promise that at some point you're going to get some sort of information in response. Like, it's the “what's in it for me?” aspect of it. We do interviews with those who've been enrolled in the study, those who could be potential enrollees in the future because they've only had one surgery. And what we're learning overall is there's this altruistic nature that people have of- they want to participate in the research because they're like, “Here's my horrible cancer experience. I know other people are going to go through this as well.” There's this guiding light of “I want to do something, and I'm not going to be the person that creates the cure, discovers the genome or whatever for this particular cancer type. But my little bit of participation in this multiplied by 20, 30, 100, 1000 people, is what is going to lead us to the next phase in development and is going to move the needle for this particular tumor type or other cancer types.” And so what I think the impact in this space and participant engagement isn't just something we figure out, like a little research method and a little finding for one small tumor type, it's like the methods to do that is the big impact. The method around participant engagement can impact even beyond the cancer community. Dr. Davide Soldato: Yeah. As Suzanne was saying, we need to be in a system that really helps us and allows us to do that. So I think that you really have a lot of things to work on inside of the network. Dr. Suzanne George: I think one thing that I would say is I think that this issue of interoperability is acknowledged as a challenge. We refer to several different initiatives across the US where this is supposed to ideally change over time. I think people want it to change over time. I think investigators at the ERTC want it to change over time. I think different countries are working on this. And I think, again, the first step is getting us at the table talking about it, and then figuring out ways to move it forward. And I think it's there. I think that there is the will. We just have to figure out the how and continue to work on that together, because there's just a tremendous opportunity. I live in the rare tumor space, and between the FDA and the EMA and the regulatory, the national and the international research groups, the patient communities, people want this to be solved and I do hope that we will be able to get there. Dr. Davide Soldato: So I would like to thank Liz and Suzanne for joining us today. Dr. Suzanne George: Thanks for having us. Liz Salmi: Thank you. Dr. Davide Soldato: Suzanne, Liz, we appreciate you sharing more on your JCO article titled, “Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality.” If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     DISCLOSURES Liz Salmi Speaking Honoria: Medscape. Research Funding (Inst): Abridge AI, Inc., Yosemite. Dr. Suzanne George Honoraria CStone Pharmaceuticals Consulting or Advisory Role Blueprint Medicines, deciphera, Bayer,  Lilly, UpToDate, Research to Practice, MORE Health, Daiichi, Kayothera, Immunicum, BioAtla   Research Funding Blueprint Medicines, Deciphera, Daiichi Sankyo RD Novare, Merck, Eisai, SpringWorks Therapeutics, TRACON Pharma, Theseus Pharmaceuticals, BioAtla, IDRx, NewBay Pharma, Acrivon Therapeutics   Patents, Royalties, Other Intellectual Property Company name: UptoDate Stock and Other Ownership Interests Abbott Laboratories and Pfizer Recipient: An Immediate Family Member

How many original castles does Japan ACTUALLY have standing? Where is Japan's oldest castle located? When counting castles in Japan, do castle ruins factor in? The Krewe is joined by William de Lange, the author of An Encyclopedia of Japanese Castles & many other Japan-related publications, to get the answer to these questions and so many more!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan! ------ Past KOJ Architecture & History Episodes ------Foreign-Born Samurai: William Adams ft. Nathan Ledbetter (Guest Host, Dr. Samantha Perez) (S5E17)Foreign-Born Samurai: Yasuke ft. Nathan Ledbetter (Guest Host, Dr. Samantha Perez) (S5E16)Change in Urban & Rural Japanese Communities ft. Azby Brown (S5E15)KOJ Podcast S5E6 - Inside Japanese Homes & Architecture ft. Azby Brown (S5E6)Kendo: The Way of the Sword ft. Alexander Bennett, 7th Dan in Kendo (S4E16)Jokichi Takamine: The Earliest Bridge Between New Orleans & Japan ft. Stephen Lyman (S4E13)The Chrysanthemum Throne ft. Dr. Hiromu Nagahara [Part 2] (S2E18)The Chrysanthemum Throne ft. Dr. Hiromu Nagahara [Part 1] (S2E17)The Age of Lady Samurai ft. Tomoko Kitagawa (S1E12)------ Links about William de Lange ------An Encyclopedia of Japanese Castles (Amazon)Japan Then & Now (Amazon, Released June 2024)Walking the Edo Sanpu (Amazon, Released August 2024)William's Website------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

In the second episode of "Empowered Intimacy: Getting Your Sexy Back After Breast Cancer," Melissa Berry and Deltra take a deep dive into the difficult challenges they faced in their marriages after their breast cancer diagnoses. They explore how to navigate intimacy, reflecting on their biggest struggles and breakthroughs. Join them as they share personal stories and offer valuable advice for those seeking to rekindle intimacy with their partners after a breast cancer diagnosis. Thank you to our sponsors, Daiichi, AstraZeneca, and Lilly, for making this series possible.  

This one goes out to all the ladies out there... well, and the fellas too if you're interested! The Krewe sits down with avid shojo enthusiast Taryn of Manga Lela Instagram/TikTok fame to talk all things shojo. Together they explore the variety of shojo genres, some challenges faced in the shojo industry, & what makes shojo different from those rambunctious shonen titles! Don't miss out!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan! ------ Past KOJ Anime/Manga/Pop Culture Episodes ------The Japanese Pop Music Scene ft. Patrick St. Michel (S5E10)Akira Toriyama: Legacy of a Legend ft. Matt Alt (S5E3)The History & Evolution of Godzilla ft. Dr. William (Bill) Tsutsui (S5E1)Thoughts on Godzilla Minus One ft. Dr. William (Bill) Tsutsui (S4Bonus)The History of Nintendo ft. Matt Alt (S4E18)Visiting Themed Cafes in Japan ft. Chris Nilghe of TDR Explorer (S4E15)Japanese Mascot Mania ft. Chris Carlier of Mondo Mascots (S4E8)Tokusatsu Talk with a Super Sentai ft. Sotaro Yasuda aka GekiChopper (S4E6)The Evolution of PokéMania ft Daniel Dockery [Part 2] (S4E3)The Evolution of PokéMania ft Daniel Dockery [Part 1] (S4E2)Japanese Independent Film Industry ft. Award Winning Director Eiji Uchida (S3E18)City Pop & Yu ft. Yu Hayami (S3E14)How Marvel Comics Changed Tokusatsu & Japan Forever ft Gene & Ted Pelc (Guest Host, Matt Alt) (S3E13)Talking Shonen Anime Series ft. Kyle Hebert (S3E10)Japanese Pro Wrestling ft. Baliyan Akki (Part 2) (S3E6)Japanese Pro Wrestling ft. Baliyan Akki (Part 1) (S3E5)Exploring Enka ft. Jerome White Jr aka ジェロ / Jero (S3E1)Japanese Arcades (S2E16)How to Watch Anime: Subbed vs. Dubbed ft. Dan Woren (S2E9)Japanese Theme Parks ft. TDR Explorer (S2E4)Manga: Literature & An Art Form ft. Danica Davidson (S2E3)The Fantastical World of Studio Ghibli ft. Steve Alpert (S2E1)The Greatest Anime of All Time Pt. 3: Modern Day Anime  (2010's-Present) (S1E18)The Greatest Anime of All Time Pt. 2: The Golden Age  (1990's-2010's) (S1E16)The Greatest Anime of All Time Pt. 1: Nostalgia (60's-80's) (S1E5)We Love Pokemon: Celebrating 25 Years (S1E3)Why Japan ft. Matt Alt (S1E1)------ Links about Taryn/Manga Lela------Taryn's LinksTaryn on TikTokTaryn on InstagramTaryn on Twitter/X------ JSNO Upcoming Events ------JSNO Event CalendarJapan Fest Sign-UpJSNO Annual Meeting RegistrationJoin JSNO Today!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.On September 23, 2024, Lifespan, a healthcare organization, laid off 20% of its executive team as part of a restructuring effort to save $6 million. The FTC sued major pharmacy benefit managers over alleged anticompetitive practices related to insulin prices. Texas Attorney General settled with a generative AI company over accuracy allegations. Steps to minimize the threat of legacy medical devices and the challenges faced by telehealth providers in navigating insurance, compliance, and cash-only models amid state regulations were discussed. The changing landscape of healthcare requires workforce planning strategies to address staffing challenges. Placing AI at the heart of healthcare to improve efficiency and patient care is also highlighted. Additionally, news on cybersecurity risks posed by legacy medical devices, challenges faced by telehealth providers, and industry developments such as new diet plans and games for falls prevention were shared. Healthcare Dive provides in-depth journalism on topics such as health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care for decision-makers in the healthcare industry.In other news, AstraZeneca and Daiichi's dato-dxd failed to extend lives in breast cancer, adding to previous setbacks in lung cancer. Bristol Myers Squibb is targeting the first new type of schizophrenia drug in three decades. A recent court ruling has revived PhRMA's legal challenge to the Inflation Reduction Act. BMS is laying off employees in New Jersey as part of cost-saving measures. BMS' karxt could soon be the first new schizophrenia drug in decades. Sanofi secured approval for Sarclisa in multiple myeloma and Athira Pharma laid off 70% of its workforce. The BACE credential can help advance a career in biotech. The ongoing battle over drug pricing was also discussed, specifically focusing on insulin and the role of pharmacy benefit managers (PBMs) in inflating costs. The U.S. Federal Trade Commission filed a lawsuit against three major PBMs for allegedly rigging the supply chain to increase insulin prices. Insulin makers like Eli Lilly have set price caps, but the FTC warned all drugmakers about raising list prices for medicines. Big pharma companies are being scrutinized for their efforts in providing access to drugs like insulin in low- and middle-income countries. A report examined the patient reach efforts of 20 major pharma companies in these regions. Overall, the industry is facing pressure to address both pricing and access issues.

Historians Nathan Ledbetter & Dr. Samantha Perez rejoin the Krewe to continue our conversation on foreign-born samurai, this time highlighting the life of William Adams! In this episode, we explore his relationships with both Japanese & non-Japanese while in Japan, the similarities between William Adams's story & House of the Dragon (what?!), how he was a big inspiration for James Clavell's classic novel (and the adaptations) Shogun... AND SO MUCH MORE!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan! ------ Past KOJ History Episodes ------Foreign-Born Samurai: Yasuke ft. Nathan Ledbetter (Guest Host, Dr. Samantha Perez) (S5E16)Kendo: The Way of the Sword ft. Alexander Bennett, 7th Dan in Kendo (S4E16)Jokichi Takamine: The Earliest Bridge Between New Orleans & Japan ft. Stephen Lyman (S4E13)How Marvel Comics Changed Tokusatsu & Japan Forever ft Gene & Ted Pelc (Guest Host, Matt Alt) (S3E13)The Chrysanthemum Throne ft. Dr. Hiromu Nagahara [Part 2] (S2E18)The Chrysanthemum Throne ft. Dr. Hiromu Nagahara [Part 1] (S2E17)The Age of Lady Samurai ft. Tomoko Kitagawa (S1E12)The Life & Legacy of Lafcadio Hearn ft. Bon & Shoko Koizumi (S1E9)------ Links about Nate ------Ubisoft's Echoes of History "Japan's First Unifier: Oda Nobunaga"Ubisoft's Echoes of History "Samurai vs Shinobi: The Tensho Iga War"Nate on BlueSky------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

With the exception of military records or a few popular cases, UFO research often gets drawn into an America-centric sphere. Because of this, or other reasons too, the phenomenon is received internationally with heavy reliance on US news and reports. But according to the US Department of Defense in 2023, Japan is a leading hotspot for UFOs as well. In June 2024, the Japanese government launched an 80-person nonpartisan group, including former defense ministers, to study UAP. Japan has three major UFO cases, named after regional areas - Kofu, Kochi, and Hokkaido - but also has mysterious stories like the Utsuro-Bune and the abundance of objects spotted over the Daiichi power plant after the 2011 disaster. Japan also has a Roswell, and a Sedona, in regard to UFO popularity and vortexes. The town is called Iinomachi in Fukushima Prefecture, just outside Fukushima city. Objects and lights have been seen here since at least the 1970s. Just north of the town in the dense forest is the IINO UFO MUSEUM, home to documents, replicas, and books on the subject. Outside is a flying saucer bus stop. Above the museum is Mount Senganmori, which features magnetic anomalies and little alien carvings along its trail. Few know that the Roswell research center and museum, founded in 1991, was not the first of its kind; Kinichi Arai, a Japanese man, formerly in the military, who died in 2002, began the first of its kind museum and research facility in 1979.-FREE ARCHIVE & RSS: https://www.spreaker.com/show/the-secret-teachings Twitter: https://twitter.com/TST___Radio Facebook: https://www.facebook.com/thesecretteachings WEBSITE (BOOKS, RESUBSCRIBE for early show access): http://thesecretteachings.info Paypal: rdgable@yahoo.com CashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.com

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.EPRO, or electronic patient-reported outcomes, is increasingly used in clinical trials to improve data accuracy, patient compliance, and reduce administrative burdens. Swing Therapeutics achieved 98% patient compliance in their pilot trial using EPRO, leading to an FDA de novo marketing authorization. EPRO boosts efficiency, saves costs, and improves trial outcomes.The BioSecure Act, which restricts contracts with certain Chinese companies in the US biotech industry, has advanced in the House but still needs Senate support. Bain Capital closed a $3 billion biotech fund and has been acquiring startup companies. Centessa's sleepiness drug showed promising results, lifting the company's shares. New data raise doubts about AstraZeneca and Daiichi's cancer treatment successor. Candid aims to prove the worth of bispecifics in autoimmune diseases.Roivant Sciences has acquired the rights to develop and commercialize Bayer's pulmonary hypertension drug, Mosliciguat, under an in-license agreement worth up to $294 million. Roivant has created a new "vant" called Vant to focus on this project. The Biosecure Act has passed through the U.S. House of Representatives and is set for a Senate vote. AstraZeneca and Daiichi Sankyo's Dato-Dxd failed to significantly improve overall survival in Phase III NSCLC trials, but there is still potential for FDA approval. Terns Pharmaceuticals announced a $125 million raise following positive Phase I data for their oral GLP-1 candidate for obesity.Old Navy is celebrating its 30th anniversary by throwing back to the '90s in a new collection and campaign to enhance its iconic brand. PayPal has launched its largest-ever US ad campaign featuring Will Ferrell, promoting the use of PayPal for both in-store and online transactions. Angela Zepeda, former Hyundai CMO, has been appointed as the global head of marketing for X. Pizza Hut is turning TikTok content into real-world currency for a promotion in the UAE, while Target is targeting pet owners with a collection designed by "fur-fluencers." Marketers are leveraging AI on mobile platforms and genAI is impacting marketing strategies.Merck's Keytruda, a leading immuno-oncology drug, has been highly successful in treating various cancers and has become the world's top-selling drug. However, determining the true value of a drug like Keytruda involves more than just sales numbers. U.S. drug pricing watchdog ICER tracks pricing decisions and their impact, but the industry is exploring new methods to factor in aspects like disability and income disparity. A new formula that considers "standard of living" is being explored to offer a different perspective on pricing in the pharmaceutical industry. As Keytruda celebrates its 10-year anniversary on the market, the impact of this cancer drug and other immunotherapies is being analyzed, along with the future direction of the field.

Joined by guest host Dr. Samantha Perez, the Krewe sits down with Princeton's Nathan Ledbetter to unpack how the term "samurai" evolved over the centuries and dig into foreign-born samurai, specifically Yasuke. Uncover everything they you need to know about the African samurai right here in this episode... AND SO MUCH MORE!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan! ------ Past KOJ History Episodes ------Kendo: The Way of the Sword ft. Alexander Bennett, 7th Dan in Kendo (S4E16)Jokichi Takamine: The Earliest Bridge Between New Orleans & Japan ft. Stephen Lyman (S4E13)How Marvel Comics Changed Tokusatsu & Japan Forever ft Gene & Ted Pelc (Guest Host, Matt Alt) (S3E13)The Chrysanthemum Throne ft. Dr. Hiromu Nagahara [Part 2] (S2E18)The Chrysanthemum Throne ft. Dr. Hiromu Nagahara [Part 1] (S2E17)The Age of Lady Samurai ft. Tomoko Kitagawa (S1E12)The Life & Legacy of Lafcadio Hearn ft. Bon & Shoko Koizumi (S1E9)------ Links about Nate ------Ubisoft's Echoes of History "Japan's First Unifier: Oda Nobunaga"Ubisoft's Echoes of History "Samurai vs Shinobi: The Tensho Iga War"Nate on BlueSky------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

With the exception of military records or a few popular cases, UFO research often gets drawn into an America-centric sphere. Because of this, or other reasons too, the phenomenon is received internationally with heavy reliance on US news and reports. But according to the US Department of Defense in 2023, Japan is a leading hotspot for UFOs as well. In June 2024, the Japanese government launched an 80-person nonpartisan group, including former defense ministers, to study UAP. Japan has three major UFO cases, named after regional areas - Kofu, Kochi, and Hokkaido - but also has mysterious stories like the Utsuro-Bune and the abundance of objects spotted over the Daiichi power plant after the 2011 disaster. Japan also has a Roswell, and a Sedona, in regard to UFO popularity and vortexes. The town is called Iinomachi in Fukushima Prefecture, just outside Fukushima city. Objects and lights have been seen here since at least the 1970s. Just north of the town in the dense forest is the IINO UFO MUSEUM, home to documents, replicas, and books on the subject. Outside is a flying saucer bus stop. Above the museum is Mount Senganmori, which features magnetic anomalies and little alien carvings along its trail. Few know that the Roswell research center and museum, founded in 1991, was not the first of its kind; Kinichi Arai, a Japanese man, formerly in the military, who died in 2002, began the first of its kind museum and research facility in 1979.-FREE ARCHIVE & RSS: https://www.spreaker.com/show/the-secret-teachingsTwitter: https://twitter.com/TST___RadioFacebook: https://www.facebook.com/thesecretteachingsWEBSITE (BOOKS, RESUBSCRIBE for early show access): http://thesecretteachings.infoPaypal: rdgable@yahoo.comCashApp: $rdgableBuy Me a Coffee: https://www.buymeacoffee.com/tstradioSUBSCRIBE TO NETWORK: http://aftermath.mediaEMAIL: rdgable@yahoo.com / TSTRadio@protonmail.com

High School Baseball: Tokyo's Kanto Daiichi Reaches Koshien Tourney Final

Baseball: Kanto Daiichi, Kyoto International Set for Summer Koshien Final Fri.

High School Baseball: Kanto Daiichi Makes Koshien Last 4 for 1st Time in 9 Yrs

What's your Japan version of "Ain't Dere No More"? Between changes within the megalopolis of Tokyo to the struggles of keeping countryside communities alive & thriving, Azby Brown returns to the podcast to discuss urban migration, depopulation, revitalization projects, centuries-old feuds raging on today... AND SO MUCH MORE!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode (timestamps [hh:mm:ss] where you can find the code)!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan!  (00:53:00)------ Links about Azby ------KOJ Podcast S5E6 - Inside Japanese Homes & Architecture ft. Azby BrownAzby's WebsiteTitles by Azby (Amazon)Azby on Twitter/XAzby on IG------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Verona wins FDA nod for COPD  The bad — FDA issues CRL to Merck-Daiichi lung cancer ADC  The ugly — Glenmark recalls 114 batches of potassium chloride capsules 

Jason T. Jacobson, MD, FHRS, Westchester Medical Center-New York Medical College, is joined by William H. Sauer, MD, FHRS, Brigham and Women's Hospital, and Christian Thomas Ruff, MD, Brigham and Women's Hospital to discuss a meta-analysis of the 2 recent randomized controlled trials of oral anticoagulation vs aspirin and placebo for atrial high rate episodes detected by cardiac implanted electronic devices. The trials included are NOAH-AFNET6 and ARTESIA, which reported discordant results. When analyzed together, this study shows that anticoagulation does decrease embolic risk in this patient population.   https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512   Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting: American College of Cardiology, Zoll Medical Corporation, Research: Abbott, Phillips, Stock, Privately Held: Atlas 5D   Contributor Disclosure(s): C. Ruff: Honoraria/Speaking/Consulting: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals, Research: Daiichi, MedImmune W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic 

What's the first thing that comes to mind when you think of a Japanese home? Is it the scent of tatami mats? Shoji-style sliding doors? What are other major components and influences that go into making the Japanese home, be it traditional or modern, as well as Japanese Architecture as a whole? With special guest Azby Brown, the Krewe is going to dig into that today!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode (timestamps [hh:mm:ss] where you can find the code)!Liquid IV Offer Link  to save 20% Off your Entire Order! (00:03:28)Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan!  (00:53:00)------ Links about Azby ------Azby's WebsiteTitles by Azby (Amazon)Azby on Twitter/XAzby on IG------ JSNO Upcoming Events ------JSNO Event Calendar2024 Matsue-New Orleans Sister City Exchange Program Application

13 years have passed since the catastrophic events of March 11th's Great East Japan earthquake & tsunami, along with the nuclear disaster at the Fukushima Daiichi Plant. Fukushima, as a prefectural community, has demonstrated incredible resiliency in its recovery efforts, but unfortunately there still is a residual stigma attached to the prefecture.  One way that Fukushima has been combating that reputation is through some creative initiatives involving education through first-hand experiences. Today, the Krewe sits down with William McMichael, an integral figure in these projects, to discuss how Fukushima University's Fukushima Ambassadors Program & Hope Tourism have helped introduce the world to Fukushima in a different way. ------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode (timestamps [hh:mm:ss] where you can find the code)!Liquid IV Offer Link  to save 20% Off your Entire Order! (00:01:06)Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan!  (00:57:54)------ Fukushima-Related Links ------Hope Tourism HomepageFukushima Ambassadors ProgramOur Fukushima (Student-run Facebook Page)Our Fukushima (Instagram)Fukushima Hamadori (VR Experience)Krewe of Japan S1E6 "3/11: A Tribute to Tohoku's Recovery & Resilience"Article - Leveraging Fukushima's "Hope Tourism" for a Disaster-Resilient Future (Japan Gov't Website)Article - Changing Hearts & Minds on Reality of Fukushima's Recovery (The Japan Times)Article - Canadian Leads Program on Fukushima for Overseas Students (Kyodo News)William McMichael on LinkedInContribute Today - Japan Disaster: Relief & Recovery via Peace Winds AmericaContribute Today - Emergency Response to Noto Peninsula Earthquake via AAR Japan------ JSNO Upcoming Events ------JSNO Event Calendar2024 Matsue-New Orleans Sister City Exchange Program Application

SEASON 5 is (almost) HERE!! This is your one week warning... as the KREWE is BACK on Friday, March 8th, 12 noon CST.  Here's a sneak peek & preview of gusts & episodes to come:- The History & Evolution of Godzilla ft. Dr. William Tsutsui- Witness Fukushima's Recovery through Educational Tourism ft. William McMichael- Japanese Self-Study Strategies ft. Walden Perry- Visit Miyagi Prefecture ft. Ryotaro Sakurai & William Woods- Japanese Homes, Architecture & Aesthetic ft. Azby Brown- A Glimpse into the World of Geisha ft. Peter Macintosh- Japanese Music Scene ft. Patrick St. Michel- Pioneering Louisiana's Only High School Japanese Program ft. Dr. Tara Sanchez- Scoping Out Shojo Anime & Manga ft. Taryn of Manga Lela- as well as some other returning guests like Matt Alt, Rob Dyer, & Kate KitagawaGet Hyped! Subscribe today on your favorite podcast app! See you on March 8th!------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode (timestamps [hh:mm:ss] where you can find the code)!Liquid IV Offer Link  to save 20% Off your Entire Order! (00:12:38)Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan!  (00:13:54)------ JSNO Upcoming Events ------JSNO Event Calendar2024 Matsue Exchange Program ApplicationJoin JSNO Today!

Show Notes: https://wetflyswing.com/568  Presented by: Togiak River Lodge, Visit Helena, MT, Smitty's Fly Box Sponsors: https://wetflyswing.com/sponsors      Today, Robert Chiasson gives us his biggest tips and tactics on finding and catching Atlantic salmon on a dry fly. He also shares a story on what it felt like to land and see this 48-inch Atlantic salmon caught on the surface with a bomber. Robert is the best person you can find if you want to fish the Margaree River and the waters of Nova Scotia and Cape Breton. You'll find out how to dead drift a fly, how to fish a seam, how to find those fish in that seam with a dry, why the reach cast is a great cast to know, and the best hook for Atlantic salmon.   Episode Chapters with Robert Chiasson on Atlantic Salmon 1:20 - Robert grew up learning to salmon fish on the Chéticamp River and eventually became a guide there. He has been guiding regularly since 1992. 2:33 - The Margaree has the largest run of Atlantic Salmon in Cape Breton. He says that it's a very friendly and relaxed river to fish in. He tells more about the Margaree for those who are planning a fly fishing trip there. 7:42 - They fish from June to the end of October. In the first couple of weeks of June, they mostly fish wet flies. By mid to late June, they're heavy into the dry fly season. About 80% of his fly choices throughout the summer are dry flies. 10:30 - In the summer, he suggests using a one-handed rod because dries are better presented with single-handed rods. He also likes switch rods. In the fall, he prefers the larger and longer spey rods. 16:10 - We dig deeper into his recommended setup for catching Atlantic salmon in his area. He also gives an important note on Atlantic salmon fishing. 19:28 - He says that when you get into the river, the first thing to look at is the configuration of the flow, so look for the fastest-moving water. And then on the edge of the fast-moving water is the seam. That's where you'll find fish. 21:30 - Robert doesn't cast his dry flies upstream a lot because he likes to lead with the fly. He tells more about his cast presentation for Atlantic salmon. 24:06 - He describes to us what a good day fishing in the Margaree River looks like. He says that one a day is a good day. 30:58 - He tells us about the biggest Atlantic salmon he has seen which he grabbed the tail with two hands. 36:30 - We dig into reels, particularly the click and pawl versus a drag reel in catching Atlantic salmon. 42:05 - He describes how he builds a leader. Straight eight is what they fished growing up. 43:40 - He tells us how different is fishing in Labrador versus in the Margaree. 49:32 - He uses the Daiichi 2110 down eye for the hooks, which is his go-to hook for dry flies.  51:30 - He gives a valuable tip on not losing an Atlantic salmon. 55:40 - He shouts out to some conservation groups such as the Margaree Salmon Association, the Nova Scotia Salmon Association, the Atlantic Salmon Federation, and the Chéticamp River Salmon Association. They have done a lot of great work on Atlantic salmon conservation. 56:40 - He says that a big factor that affects the Atlantic salmon runs is commercial fishing in Greenland. 58:54 - He recommends some places to stay in for those who are planning to go to their area for a fly fishing trip. 1:00:03 - He tells us some history on the Margaree and Cape Breton. Show Notes: https://wetflyswing.com/568 

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have several news updates from the industry. Let's dive in.Cigna has sold its Medicare businesses to HCSC for $3.7 billion, exiting a sector that has seen its earnings potential shrink. Despite the sale, Cigna still sees Medicare Advantage as an area for future growth. In other news, the No Surprises Act prevented 10 million surprise bills in the first nine months of 2023, according to insurer groups AHIP and BCBSA. However, they also criticized providers for allegedly abusing the billing dispute resolution process set up by the law. Tenet Healthcare plans to sell four California hospitals to UCI Health for $975 million as part of its efforts to reduce debt. An AI-powered solution is being touted as a way to alleviate the critical shortage of medical coders and boost efficiency and revenue in healthcare systems.In the biotech world, Arch is raising $3 billion for startup investing, continuing its track record of creating and investing in biotech startups. Vertex's non-opioid drug showed positive results in a major trial for pain relief, although it fell short compared to a widely prescribed opioid on a secondary goal. Cell therapy for lupus is gaining attention, with several drugmakers conducting trials in this area. Biogen has decided to discontinue its controversial drug Aduhelm and return the rights to the original developer. AstraZeneca and Daiichi are seeking FDA approval for their drug Enhertu as a "tumor agnostic" treatment. Roche has made changes to its early-stage pipeline, focusing on experimental programs for obesity.In recent developments, Philips has stopped selling sleep and respiratory devices in the US due to a consent decree from the FDA. Teleflora used a documentary approach in its marketing campaign to overcome cynicism about love, while Lay's released time-loop ads inspired by the movie "Groundhog Day." Ocean Spray revealed its first major brand overhaul in over 20 years, and Miller Lite turned fans into walking beer ads for the Super Bowl. McDonald's also made headlines with its Hamburglar character hitting the road in a getaway vehicle. Pepsi Wild Cherry created excitement around the Super Bowl with a Vegas sphere takeover.Cigna is still interested in the Medicare Advantage market despite selling its Medicare division. Providence plans to settle allegations of not fulfilling charity care obligations. Walgreens has confirmed additional layoffs as part of its ongoing efforts to achieve cost savings. The Department of Health and Human Services has finalized a rule on telehealth at opioid treatment programs. A new study found that the availability of telehealth for mental healthcare varies by state. Healthcare executives must consider workforce and consumer concerns about generative AI, according to a survey.Alto Neuroscience and Fractyl Health have both gone public in separate IPOs, joining the recent surge of biotech IPOs. The CMS has sent initial price proposals to drugmakers as part of efforts to reform drug pricing. Kyverna Therapeutics is planning an IPO to support the development of its anti-CD19 CAR-T therapies. The Department of Health and Human Services released new data showing that Americans pay significantly more for prescription drugs compared to other developed countries. The ASGCT Annual Meeting will cover topics such as genome editing, muscular dystrophy, and cell and gene therapy.In financial news, AbbVie reported a beat in its Q4 earnings but expects sales decline in oncology and immunology. Bristol Myers Squibb exceeded Q4 estimates and is looking towards new products and M&A following exclusivity loss. Merck posted $60 billion in sales for 2023 driven by Keytruda and HPV vaccine. GlaxoSmithKline saw an increase in sales thanks to vaccines for RSV and shingles. Takeda reported lower profits but closed a $300 million deal with Protagonis

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Sarepta Therapeutics has released data on its new drug for Duchenne muscular dystrophy, showing potent boosting of dystrophin protein production. However, some side effects, including electrolyte imbalances, were also highlighted. Astrazeneca and Daiichi are seeking FDA approval for their drug Enhertu as a "tumor agnostic" treatment, and the FDA is currently reviewing their application. Bristol Myers has received positive data from a trial of a subcutaneous formulation of Opdivo in kidney cancer, showing similar efficacy to the intravenous formulation. Biotech IPOs continue to be an important source of funding for the industry, with Alto Neuroscience and Fractyl Health preparing for initial stock offerings. Merck Manuals is focusing on a "one health" approach, integrating human, animal, and environmental health in medical education and practice.Philips has announced that it will stop selling sleep and respiratory devices in the US due to a consent decree from the FDA. This decision comes as Philips faces regulatory scrutiny and potential legal action related to quality issues with its sleep apnea devices. Medical device companies Stryker, Boston Scientific, and BD are set to post their earnings this week. Absolutions has received FDA breakthrough designation for its abdominal wall closure device, aiming to reduce the risk of hernia by distributing suture tension over a large area of tissue. Globus has laid off employees from NuVasive following their merger. Masimo has forced Apple to redesign its smartwatches in a long-running patent dispute.The pharmaceutical industry is in a race to develop groundbreaking drugs for pain relief. Tanezumab, developed by Eli Lilly and Pfizer, was dropped due to safety concerns. Attention has turned to Vertex Pharmaceuticals' candidate vx-548, which has shown positive results in phase 2 trials for chronic nerve pain. South Rampart Pharma has won fast track designation for its novel drug that activates pain signaling pathways without causing liver and kidney toxicities. Tonix Pharmaceuticals is repurposing an existing technology for the treatment of fibromyalgia, with positive late-stage results. These developments offer hope for patients suffering from chronic pain conditions and could generate significant revenue for the companies involved.Overall, these developments highlight ongoing challenges and changes in the medtech industry, including regulatory scrutiny, mergers, and patent disputes. Medtech companies must navigate these complexities while leveraging connected ecosystems, data, and strategic planning to drive innovation in healthcare.Thank you for tuning in to Pharma and Biotech daily. Stay informed, stay ahead.

Daiichi Sankyo has drawn more value from its antibody-drug conjugate pipeline via a $4 billion deal with Merck & Co. On the latest BioCentury This Week podcast, BioCentury's editors analyze the deal in the context of the burgeoning ADC space and size up the assets that Merck is in-licensing as well as how the deal fits with Daiichi's pipeline strategy.The editors break down Monday's $7.1 billion deal by Roche for the Telavant subsidiary of Roivant Sciences, the latest in the evolving TL1A space; and offer highlights from BioCentury's deep dive into how academics and biotechs are expanding the therapeutic potential of base editors.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Daiichi's huge ADC deal with Merck; mixed data for Rybrevant at ESMO; Pfizer girds for cost cuts; myeloma helps J&J's Q3; and five key points for cell and gene Meeting on the Mesa. https://scrip.citeline.com/SC149230/Quick-Listen-Scrips-Five-MustKnow-Things

Show Notes: https://wetflyswing.com/516  Presented by: Stonefly Nets, Daiichi, Angler's Coffee Sponsors: https://wetflyswing.com/sponsors       Matt Lewis of Redeye Bass Fly Fishing shares his insights on redeye bass and their vital conservation efforts in the Native Fish Coalition to preserve its native population. We will also uncover the unique characteristics of redeye bass, their habitat preferences, and the exciting pursuit of the Redeye Slam. Episode Chapters with Matt Lewis on Redeye Bass  1:40 - Matt tells us how he got into fly fishing. Initially, his focus was to become a medical doctor. He spent decades doing cancer research, but his outlet has always been fishing. 3:15 - One of his friends introduced him to redeye bass fly fishing. He grew up in Alabama where the species is abundant. When his interest grew, he got frustrated that there were limited resources for that species at that time. 6:00 - That led him to write and release a book in January 2018 entitled Fly Fishing for Redeye Bass: An Adventure Across Southern Waters. 9:38 - We dig into the distribution of redeye and other similar species. They exist mostly in Alabama, Georgia, and South Carolina. 13:50 - He tells us what a fall line is. 16:00 - He talks about fishing redeye bass which he says are aggressive top-water eaters very much like brook trout. His favorite bug to use is chartreuse or yellow popper. Any kind of foam attractor like hopper patterns also works well. 18:23 - He mentions East Alabama Fly Fishing which offers guide services in Tallapoosa River for bass fishing. 19:50 - He shares some concerns about the population of redeye bass such as the moving of species to where they don't belong and habitat disturbance. These would have long-term effects on their native population. 28:00 - He briefly talks about their spawning. 29:36 - I ask him about how he got connected with Dorsal Outdoors leading them to make a film called "A Slam That Saves". The film features him and Mary Beth Meeks attempting to catch a "Redeye Slam" in one day. 38:46 - The biggest conservation group that he has worked with was the Native Fish Coalition, a national non-profit organization. He also has worked as an advisory board member for a local riverkeeper organization. 43:35 - He encourages everyone to educate themselves and others on the danger of moving fish around, and to get involved with conservation groups. 45:55 - We give a shout-out to Angler's Coffee. Matt prefers dark roast coffee with bold flavors like the Muddler's Blend from Angler's Coffee. He also gives a shout-out to his go-to fly shop which is the Deep South Outfitters. 48:32 - Aside from redeye bass, the other top species you can fish in Alabama are smallmouth bass, largemouth bass, spotted bass, and panfish among others. He's currently writing a fly fishing guidebook for Alabama. 52:36 - Matt says pursuing redeye bass fishing is growing the sport because it's the easiest entry to fly fishing. 55:06 - He shares a fun fact about the species. 56:53 - I ask about the smallmouth bass distribution. 57:30 - He likes listening to podcasts when driving. Aside from listening to our podcast, he also likes The MeatEater Podcast and The Orvis Fly-Fishing Podcast wherein he was also interviewed last year. 58:48 - He gives a call to action to support the conservation of the redeye bass population. Show Notes: https://wetflyswing.com/516 

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Erik Andrews, MD, MPH, and Christian Thomas Ruff, MD, MPH, of Brigham and Women's Hospital to discuss Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. In the FRAIL-AF clinical trial, there were more bleeding events when elderly patients were switched from warfarin to rivaroxaban, apixaban, edoxaban, or dabigatran.   https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485   Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic   Contributor Disclosure(s): E. Andrews: No relevant financial relationships with ineligible companies to disclose.  C. Ruff: Honoraria/Speaking/Consulting Fee: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals; Research (Contracted Grants for PIs Named Investigators Only): Daiichi, MedImmune

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Biomarin's next chapter; Amgen's obesity plans; Daiichi's new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn's. https://scrip.citeline.com/SC149072/Quick-Listen-Scrips-Five-MustKnow-Things

Show Notes:  https://wetflyswing.com/502 Presented By: Togens Fly Shop, Daiichi, Jackson Hole Fly Company, Angler's Coffee Today we dive into the fascinating world of fishery science and conservation with James Suleski of the Pennsylvania Native Fish Coalition. James is on a mission to bridge the gap between anglers and fisheries scientists. We explore the intricate challenges faced by native brook trout, like climate change and the impact of invasive brown trout. Tune in to learn more about the strategies, misconceptions, and hopes for protecting these precious aquatic inhabitants. Native Fish Coalition Show Notes with James Suleski 2:45 - James is a board member of the Pennsylvania Native Fish Coalition, where he specializes in science communication. He distills complex fishery science research into easily understandable messages for the general audience. 03:55 - Native Fish Coalition is a grassroots, donor-funded 501(c)(3) nonprofit dedicated to protecting, restoring, and advocating for native fish. 04:20 - James says he's just your regular angler who found his way into Pennsylvania's fly fishing scene after college and grad school. There he noticed that anglers and fisheries scientists had completely different takes on what was going on with native fish species, especially brook trout. Native Brook Trout in Pennsylvania 06:00 - James highlights two critical factors affecting native brook trout: climate change and invasive fish species. While climate change is widely acknowledged as a significant issue, the impact of invasive species is often overlooked in discussions about brook trout conservation. 14:40 - James clarifies the misconception about the term "invasive brown trout". He emphasizes that efforts to address this issue are not about removing them from well-known fisheries on a large scale. Instead, it involves carefully selected smaller streams with barriers to protect native brook trout populations. 17:40  - Selective conservation efforts in smaller streams where it's ecologically and socially feasible include stocking reform, catch and release regulations, and controlled harvest of non-native trout species. 41:00 - James remains optimistic because Pennsylvania hasn't yet explored cost-effective management strategies. One such approach is stopping the stocking invasive trout, which has shown promise in small streams. 47:00 - James highlights Dr. Shannon White's research on brook trout, which challenged the previously held belief that brook trout were sedentary. 58:00 - According to the International Union for Conservation of Nature, roughly a third of freshwater fish are at risk of extinction. 1:00:00 - Native Fish Coalition's strategy involves educating the public, encouraging them to reach out to legislators for stocking reforms, and fostering dialogue to promote responsible conservation practices. Show Notes:  https://wetflyswing.com/502

After the 2011 Fukushima Daiichi disaster in Japan there was an outcry over nuclear energy, but only for a short period of time. The mainstream media covered the story for ratings, usually downplaying the dangers, while the alternative media painted the meltdown as the end of all life as we know it. Radioisotopes were found a year later in kelp near Southern California; radioactive material was also found in San Francisco as recent as 2018; and even NOAA Fisheries found elevated levels of radiation in some tuna fish. In 2017 the story became widespread again with reports of massive radiation spikes up to 530 sieverts per hour inside Reactor 2. This resulted in robots being destroyed when sent inside. The Japanese government also coerced residents back into the surrounding countryside sooner than later after the disaster under threats of losing financial assistance. Now the Japanese government and TEPCO, Tokyo Electric Power Co., are going ahead with plans to dump 540 Olympic swimming pools worth of tritium-contaminated wastewater into the ocean. Reportedly, the “water was treated with a special filtering system that remove all the radioactive elements except tritium.” What gets forgotten is that it's not so much the current water dumping that is the issue, but the disaster itself which dumped unknown amounts of other radioactive materials into the ocean and atmosphere, including high levels of cesium which was registering at 250 times the acceptable safe limit in 2012, and again in 2019, although at slightly lesser levels.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5328407/advertisement

It seems this country has become numb to the Opioid Crisis. We can not bury our heads, mandate it away, or think it only happens to bad people. Hopefully, it won't take a personal tragedy in someone's life to understand that this crosses all demographics. We have had Hamilton on before to discuss his alcohol use disorder, but today he will tell us how a back surgery led him to a long relationship with opioids. Let's stop stigmatizing this crisis and come together for solutions as this affects everyone.Hamilton Baiden is Youturn Health's CEO. Prior to joining Youturn Health, Hamilton was Executive Vice President of Sales at Avella Specialty Pharmacy where he oversaw the growth of the business from a small regional pharmacy to the largest independent specialty pharmacy in the nation. His knowledge and understanding of the pharmacy industry were developed throughout his professional career, working in various roles for prominent pharmaceutical manufacturing companies, including MedImmune, Serono, Daiichi, and Sanofi. A graduate of The Citadel in Charleston, SC, with strong ties to his community, Hamilton served as Chairman of the Board of Directors for a nonprofit organization dedicated to animal welfare, Altered Tails, and currently serves on the National Board of the American Liver Foundation Southwest Division. Hamilton is also in recovery and committed to helping others.

Seaver Wang's academic training in oceanography makes him a knowledgeable source for discussing Japan's release of tritiated water from Fukushima Daiichi into the Pacific Ocean, a process that began last week. In addition, Wang, the co-director of the climate and energy program at the Breakthrough Institute,  discusses future demand for metals and minerals, “radiophobia,” the challenges facing nuclear power, solar supply chains, and China's “cultural erasure” of the Uyghur population in Xinjiang province. (Recorded August 28, 2023)